Covista earnings release, August 6, 2026

Covista Inc. (CVSA) · Form 8-K, Item 2.02 · Filed · SEC filing

Investor Contact:

Jeremy Cohen

Investor.Relations@Covista.com

+1 312-906-6600

​

Media Contact:

Maureen Bender

CovistaMedia@Covista.com

+1 313-319-4732

Covista Announces Fiscal Year 2026 Results, Exceeds Financial Guidance;

Initiates Fiscal Year 2027 Guidance

Total Q4 enrollment up 8.4% and revenue up 9.7% YoY

Chamberlain accelerates total enrollment growth to 1.6%

Revenue up 9.3% YoY for fiscal year 2026

Fiscal year 2026 diluted earnings per share $7.04; Adjusted EPS $8.25, growth of 23.7% YoY

Fourth quarter highlights

Fiscal year highlights

Fiscal year capital allocation

Fiscal year 2027 guidance

​

​

CHICAGO – August 6, 2026 – Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported fourth quarter and fiscal year 2026 results (ended June 30, 2026). The Company completed its three-year

Growth with Purpose strategy and now embarks on its

Purpose at Scale strategy, leading the transformation of higher education by training the next generation of healthcare professionals at an industry-leading scale.

"We completed

Growth with Purpose in a position of strength, exceeding both our fiscal 2026 and long-term financial targets. The strategy produced exactly what it was designed to deliver: compounding returns built on sustained investment, deliberate positioning, and a relentless focus on student outcomes. But the results go beyond the financial. They reflect a deeper transformation and vision to be the destination where healthcare ambitions are made possible, graduating professionals who don't just fill jobs, but strengthen the communities where they serve,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “We enter our next chapter,

Purpose at Scale, powered by an operating model that converts durable healthcare demand into sustainable, profitable growth. Applying that discipline to a larger opportunity is how we create value for our stakeholders and help close the healthcare workforce shortage the country urgently needs solved."

Financial Highlights

Selected financial data for the three months ended June 30, 2026:

Selected financial data for the fiscal year ended June 30, 2026:

​

Business Highlights

Segment Highlights

Chamberlain

​

​

Walden

​

​

Medical and Veterinary

​

​

Fiscal Year 2027 Outlook

Covista initiates guidance for fiscal year 2027, including:

​

“We are entering the first year of

Purpose at Scale with enhanced momentum, reflecting our strong finish to fiscal year 2026. The overall financial performance trajectory allows us to provide compelling guidance for fiscal year 2027. Taken together, we are tracking ahead of where we expected we would be with regard to our long-term targets,” said Beard.

​

Conference Call and Webcast Information

Covista will hold a conference call to discuss its fourth quarter and fiscal year 2026 results today at 4:00 p.m. CT (5:00 p.m. ET).

​

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13761006. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com.

​

Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13761006, or visit the Covista investor relations website.

​

About Covista

Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and supported by a community of 400,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit Covista.com and follow us on LinkedIn, Instagram and YouTube.

​

Financial statements

Income Statement

Three Months Ended — Chamberlain (in millions)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Three Months Ended – June 30, – % ChangeYear Ended – June 30, – 2026Year Ended – June 30, – 2025Year Ended – June 30, – % Change
Revenue190.2184.33.2%750.2725.83.4%
Operating Income36.335.71.6%141.6151.5-6.5%
Adj. Operating Income36.335.71.6%143.6153.4-6.3%
Adj. EBITDA46.8453.8%185.5191.4-3.1%
Total Students (2)39,50138,8911.6%

Income Statement

Three Months Ended — Walden (in millions)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Three Months Ended – June 30, – % ChangeYear Ended – June 30, – 2026Year Ended – June 30, – 2025Year Ended – June 30, – % Change
Revenue210.8182.215.7%804.9693.416.1%
Operating Income59.84435.9%227.8177.928.0%
Adj. Operating Income62.846.834.3%239.7183.630.6%
Adj. EBITDA69.752.732.3%268206.529.8%
Total Students (2)54,85148,11614.0%

Income Statement

Three Months Ended — Medical and Veterinary (in millions)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Three Months Ended – June 30, – % ChangeYear Ended – June 30, – 2026Year Ended – June 30, – 2025Year Ended – June 30, – % Change
Revenue100.390.610.7%398.9369.18.1%
Operating Income16.714.912.1%79.168.815.0%
Adj. Operating Income16.715.110.4%8069.315.5%
Adj. EBITDA22.52012.3%102.888.815.7%
Total Students (2)5,1204,7737.3%

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Revenue501,382457,1061,954,0851,788,290
Operating cost and expense:Cost of educational services216,749198,930833,660771,430
Operating cost and expense:Student services and administrative expense188,089180,863730,720672,004
Operating cost and expense:Restructuring expense1,1013886,3293,314
Operating cost and expense:Total operating cost and expense405,939380,1811,570,7091,446,748
Operating cost and expense:Operating income95,44376,925383,376341,542
Operating cost and expense:Interest expense-9,799-10,853-45,435-52,318
Operating cost and expense:Other income, net2,7562,5117,1789,290
Operating cost and expense:Income from continuing operations before income taxes88,40068,583345,119298,514
Operating cost and expense:Provision for income taxes-16,240-14,121-77,744-65,837
Operating cost and expense:Income from continuing operations72,16054,462267,375232,677
Discontinued operations:(Loss) income from discontinued operations before income taxes-426-346-21,2365,870
Discontinued operations:(Provision for) benefit from income taxes-13965,427-1,482
Discontinued operations:(Loss) income from discontinued operations-439-250-15,8094,388
Discontinued operations:Net income and comprehensive income71,72154,212251,566237,065
Basic:Continuing operations2.121.517.636.27
Basic:Discontinued operations-0.01-0.01-0.450.12
Basic:Total basic earnings per share2.111.57.186.39
Diluted:Continuing operations2.081.457.496.07
Diluted:Discontinued operations-0.01-0.01-0.440.11
Diluted:Total diluted earnings per share2.061.447.046.18
Weighted-average shares outstanding:Basic shares34,03236,03435,04537,085
Weighted-average shares outstanding:Diluted shares34,76337,58435,71538,334

Income Statement

Three Months Ended — (in thousands)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Three Months Ended – June 30, – Increase/(Decrease) – $$Three Months Ended – June 30, – Increase/(Decrease) – %Year Ended – June 30, – 2026Year Ended – June 30, – 2025Year Ended – June 30, – Increase/(Decrease) – $$Year Ended – June 30, – Increase/(Decrease) – %
Chamberlain:Operating income36,31635,7395771.6%141,618151,455-9,837-6.5%
Chamberlain:Restructuring expense2,0241,912112
Chamberlain:Adjusted operating income36,31635,7395771.6%143,642153,367-9,725-6.3%
Chamberlain:Operating margin19.1%19.4%18.9%20.9%
Chamberlain:Adjusted operating margin19.1%19.4%19.1%21.1%
Walden:Operating income59,75343,98215,77135.9%227,788177,91149,87728.0%
Walden:Restructuring expense255255715715
Walden:Amortization of acquired intangible assets2,8052,80511,22011,220
Walden:Litigation reserve-5,5505,550
Walden:Adjusted operating income62,81346,78716,02634.3%239,723183,58156,14230.6%
Walden:Operating margin28.3%24.1%28.3%25.7%
Walden:Adjusted operating margin29.8%25.7%29.8%26.5%
Medical and Veterinary:Operating income16,65614,8641,79212.1%79,11068,79810,31215.0%
Medical and Veterinary:Restructuring expense218-218855454401
Medical and Veterinary:Adjusted operating income16,65615,0821,57410.4%79,96569,25210,71315.5%
Medical and Veterinary:Operating margin16.6%16.4%19.8%18.6%
Medical and Veterinary:Adjusted operating margin16.6%16.6%20.0%18.8%

Income Statement

Three Months Ended — (in thousands)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Three Months Ended – June 30, – Increase/(Decrease) – $$Three Months Ended – June 30, – Increase/(Decrease) – %Year Ended – June 30, – 2026Year Ended – June 30, – 2025Year Ended – June 30, – Increase/(Decrease) – $$Year Ended – June 30, – Increase/(Decrease) – %
Chamberlain:Adjusted operating income (GAAP)36,31635,7395771.6%143,642153,367-9,725-6.3%
Chamberlain:Depreciation5,9655,50346223,07321,6871,386
Chamberlain:Amortization of cloud computing implementation assets2,0697801,2897,6893,0334,656
Chamberlain:Stock-based compensation2,4193,019-60011,12813,309-2,181
Chamberlain:Adjusted EBITDA (non-GAAP)46,76945,0411,7283.8%185,532191,396-5,864-3.1%
Chamberlain:Adjusted EBITDA margin (non-GAAP)24.6%24.4%24.7%26.4%
Walden:Adjusted operating income (GAAP)62,81346,78716,02634.3%239,723183,58156,14230.6%
Walden:Depreciation2,0141,993218,1037,421682
Walden:Amortization of cloud computing implementation assets1,9167601,1566,9393,0023,937
Walden:Stock-based compensation2,9263,123-19713,19012,477713
Walden:Adjusted EBITDA (non-GAAP)69,66952,66317,00632.3%267,955206,48161,47429.8%
Walden:Adjusted EBITDA margin (non-GAAP)33.0%28.9%33.3%29.8%
Medical and Veterinary:Adjusted operating income (GAAP)16,65615,0821,57410.4%79,96569,25210,71315.5%
Medical and Veterinary:Depreciation3,0802,75532512,01610,8531,163
Medical and Veterinary:Amortization of cloud computing implementation assets7193064132,5551,2081,347
Medical and Veterinary:Stock-based compensation2,0221,8731498,2437,486757
Medical and Veterinary:Adjusted EBITDA (non-GAAP)22,47720,0162,46112.3%102,77988,79913,98015.7%
Medical and Veterinary:Adjusted EBITDA margin (non-GAAP)22.4%22.1%25.8%24.1%
Home Office:Adjusted operating loss-14,906-10,100-4,806-47.6%-43,843-36,030-7,813-21.7%
Home Office:Depreciation164184-20658741-83
Home Office:Stock-based compensation2,7462,3943528,6558,318337
Home Office:Adjusted EBITDA-11,996-7,522-4,474-59.5%-34,530-26,971-7,559-28.0%
Covista:Net income (GAAP)71,72154,21217,50932.3%251,566237,06514,5016.1%
Covista:Loss (income) from discontinued operations43925018915,809-4,38820,197
Covista:Interest expense9,79910,853-1,05445,43552,318-6,883
Covista:Other income, net-2,756-2,511-245-7,178-9,2902,112
Covista:Provision for income taxes16,24014,1212,11977,74465,83711,907
Covista:Depreciation and amortization18,73215,0863,64672,25359,16513,088
Covista:Stock-based compensation10,11310,409-29641,21641,590-374
Covista:Restructuring expense1,1013887136,3293,3143,015
Covista:Litigation reserve-5,5505,550
Covista:Asset impairments6,442-6,442
Covista:Strategic advisory costs1,5306,900-5,37018,56212,0006,562
Covista:Loss on assets held for sale490-490490-490
Covista:Debt modification costs712-712
Covista:Adjusted EBITDA (non-GAAP)126,919110,19816,72115.2%521,736459,70562,03113.5%
Covista:Adjusted EBITDA margin (non-GAAP)25.3%24.1%26.7%25.7%

Income Statement

Three Months Ended — Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Diluted earnings per share (GAAP)2.061.447.046.18

Income Statement

(in thousands)

Year Ended – June 30, 2026June 30, 2026
Covista:Net income (GAAP)251,566
Covista:Loss from discontinued operations15,809
Covista:Interest expense45,435
Covista:Other income, net-7,178
Covista:Provision for income taxes77,744
Covista:Depreciation and amortization72,253
Covista:Stock-based compensation41,216
Covista:Restructuring expense6,329
Covista:Strategic advisory costs18,562
Covista:Adjusted EBITDA (non-GAAP)521,736
Covista:Total long-term debt principal673,000
Covista:Less: Cash and cash equivalents-406,316
Covista:Net debt (non-GAAP)266,684
Covista:Net leverage (non-GAAP)0.5x

Balance Sheet

(in thousands)

June 30, – 2026June 30, – 2025
Current assets:Cash and cash equivalents406,316199,601
Current assets:Restricted cash1,4381,563
Current assets:Accounts and financing receivables, net169,561146,189
Current assets:Prepaid expenses and other current assets75,12668,837
Current assets:Total current assets652,441416,190
Noncurrent assets:Property and equipment, net302,649256,131
Noncurrent assets:Operating lease assets204,364191,194
Noncurrent assets:Deferred income taxes32,956
Noncurrent assets:Intangible assets, net754,254765,474
Noncurrent assets:Goodwill961,262961,262
Noncurrent assets:Other assets, net137,738129,145
Noncurrent assets:Total noncurrent assets2,360,2672,336,162
Noncurrent assets:Total assets3,012,7082,752,352
Current liabilities:Accounts payable124,763105,017
Current liabilities:Accrued payroll and benefits78,66976,374
Current liabilities:Accrued liabilities94,36477,286
Current liabilities:Deferred revenue259,125214,091
Current liabilities:Current operating lease liabilities34,79935,159
Current liabilities:Current portion of long-term debt5,100
Current liabilities:Total current liabilities596,820507,927
Noncurrent liabilities:Long-term debt657,750552,669
Noncurrent liabilities:Long-term operating lease liabilities207,846186,172
Noncurrent liabilities:Deferred income taxes61,78231,856
Noncurrent liabilities:Other liabilities42,32540,103
Noncurrent liabilities:Total noncurrent liabilities969,703810,800
Noncurrent liabilities:Total liabilities1,566,5231,318,727
Commitments and contingenciesTotal shareholders' equity1,446,1851,433,625
Commitments and contingenciesTotal liabilities and shareholders' equity3,012,7082,752,352

Cash Flow

Year Ended June 30, — (in thousands)

Year Ended June 30, – 2026Year Ended June 30, – 2025
Operating activities:Net income251,566237,065
Operating activities:Loss (income) from discontinued operations15,809-4,388
Operating activities:Income from continuing operations267,375232,677
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation41,21641,590
Adjustments to reconcile net income to net cash provided by operating activities:Amortization and impairments to operating lease assets27,94632,543
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation43,85040,702
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of acquired intangible assets11,22011,220
Adjustments to reconcile net income to net cash provided by operating activities:Amortization and write-off of debt discount and issuance costs7,6215,985
Adjustments to reconcile net income to net cash provided by operating activities:Provision for credit losses68,76563,237
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes68,35218,413
Adjustments to reconcile net income to net cash provided by operating activities:Loss on disposals and impairments of property and equipment7432,527
Adjustments to reconcile net income to net cash provided by operating activities:Gain on investments-1,720-1,074
Adjustments to reconcile net income to net cash provided by operating activities:Loss on assets held for sale490
Changes in assets and liabilities:Accounts and financing receivables-89,263-80,820
Changes in assets and liabilities:Prepaid expenses and other current assets8,4235,546
Changes in assets and liabilities:Cloud computing implementation assets-13,954-32,823
Changes in assets and liabilities:Accounts payable6,192140
Changes in assets and liabilities:Accrued payroll and benefits2,4945,144
Changes in assets and liabilities:Accrued liabilities-9,697-15,948
Changes in assets and liabilities:Deferred revenue50,92534,273

Cash Flow

Twelve Months Ended — (in thousands)

Twelve Months Ended – FY25 – Q4Twelve Months Ended – FY26 – Q1Twelve Months Ended – FY26 – Q2Twelve Months Ended – FY26 – Q3Twelve Months Ended – FY26 – Q4
Net cash provided by operating activities-continuing operations (GAAP)333,734374,796427,890406,335470,796
Capital expenditures-50,327-55,936-59,880-69,872-77,696
Free cash flow (non-GAAP)283,407318,860368,010336,463393,100
Full release

Cautionary Disclosure Regarding Forward-Looking Statements

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,”

“expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you... (truncated)perience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

​

A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Covista's results in accordance with GAAP.

###

​

Covista Inc.

Consolidated Balance Sheets

(unaudited)

(in thousands)

​

​

​

​

​

​

​

​

Covista Inc.

Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

​

​

​

​

​

​

Covista Inc.

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Segment Revenue

(unaudited)

(in thousands)

​

​

​

Covista Inc.

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:

Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, tax benefit due to change in unrecognized tax benefits, and loss (income) from discontinued operations.

Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, tax benefit due to change in unrecognized tax benefits, and loss (income) from discontinued operations.

Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs.

Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.

Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.

Net debt – Defined as total long-term debt principal less cash and cash equivalents.

Net leverage – Defined as net debt divided by adjusted EBITDA.

A description of special items in our non-GAAP financial measures described above are as follows:

Covista Inc.

Adjusted Operating Income

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Adjusted EBITDA

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Adjusted Earnings

(unaudited)

(in thousands, except per share data)

​

(1)

Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

​

Note: May not sum due to rounding.

(1)

Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

​

Covista Inc.

Free Cash Flow

(unaudited)

(in thousands)

​

​

​

​

​

Covista Inc.

Net Leverage

(unaudited)

(in thousands)

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Covista earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.